Tevimbra
Tevimbra Approved for Treatment of Gastric and Gastroesophageal Junction Cancers in Combination With Chemo
The FDA has approved tislelizumab in combination with chemotherapy for the first-line treatment of unresectable or ...
JANUARY 15, 2025
Tevimbra Approved for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemo
The FDA approved tislelizumab-jsgr as monotherapy for certain adult patients with esophageal squamous cell ...
MARCH 19, 2024
Load more